A unique role for apoC-III in intestinal lipoprotein synthesis and secretion

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Apolipoprotein C-III (apoC-III) is an exchangeable lipoprotein produced by both the liver and intestine. The plasma concentration of apoC-III is elevated in type 1 diabetics and is an independent predictor of cardiovascular disease. ApoC-III is found on triglyceride-rich lipoproteins and high-density lipoproteins, and acts to raise plasma triglyceride levels through the inhibition of lipoprotein lipase activity, and by interfering with lipoprotein clearance by the liver. While significant progress has been made in understanding the mechanisms that govern these effects, the role of apoC-III in intestinal lipoprotein synthesis and secretion remains undefined. We have recently observed that whole body overexpression of apoC-III in apoC-III transgenic (Tg) mice results in inhibited intestinal TAG secretion from the enterocyte into lymph coupled with the retention of free fatty acid (FFA) and monoacylglycerol (MAG) precursors and a decrease in TAG within the enterocyte. This inhibitory effect of apoC-III in the intestinal cell is in contrast to studies in hepatocytes, which have correlated apoC-III expression with increased VLDL secretion. Our overall hypothesis is that apoC-III plays a unique role in the intestine and liver in lipoprotein synthesis and secretion. We will test the 3 possible mechanisms by which increased apoC-III would lead to inhibited TAG synthesis (that apoC-III directly inhibits 1) MGAT and/or DGAT enzyme activity; 2) FFA trafficking to the ER; or 3) the activation of FFA to fatty acyl- CoA) and will delineate a mechanistic role for apoC-III in intestinal lipid absorption and secretion. We will also investigate the functional importance of apoC-III in the intestine versus the liver using adenovirus to knockdown and overexpress apoC-III in mouse liver. Finally, we will investigate the role of human apoC-III polymorphisms on intestinal TAG secretion in primary mouse enteroid cultures. The completion of these aims will provide key knowledge about the role of apoC-III in mediating intestinal lipoprotein secretion and the potential of intestinal apoC-III as a therapeutic target.